Merus NV (NASDAQ:MRUS) reached a new 52-week high on Friday . The stock traded as high as $10.89 and last traded at $10.54, with a volume of 20,268 shares trading hands. The stock had previously closed at $8.50.

Several research firms recently weighed in on MRUS. Citigroup Inc. began coverage on Merus NV in a research report on Monday, June 13th. They set a “buy” rating and a $14.00 price target on the stock. Wedbush began coverage on Merus NV in a report on Monday, June 13th. They issued an “outperform” rating and a $14.00 target price on the stock. Guggenheim began coverage on Merus NV in a report on Monday, June 13th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Jefferies Group reissued a “buy” rating and issued a $19.00 target price on shares of Merus NV in a report on Wednesday, July 13th.

The company’s market cap is $90.93 million. The company has a 50 day moving average of $8.36 and a 200-day moving average of $8.63.

Merus BV is a biotechnology company based in the Netherlands. It develops therapeutic monoclonal antibodies that address multiple targets in the treatment of cancer. The Company’s technology base includes transgenic MeMo mouse, which produces therapeutic human antibodies. The technologies are used to create the Company’s products, notably Biclonics, antibodies used for the treatment of tumors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.